Arvinas presented phase 1 multiple‑dose data for ARV‑102, a PROTAC degrader targeting LRRK2 in Parkinson’s disease, showing approximately 50% or greater reduction of LRRK2 protein in cerebrospinal fluid by day 14 and sustained through day 28. The randomized, placebo‑controlled MD cohort evaluated oral doses from 20–80 mg daily and reported dose‑dependent CSF exposure consistent with brain penetration. The company also reported reductions in LRRK2‑linked endolysosomal and neuroinflammatory biomarkers. Safety and tolerability were acceptable across dose levels in the short 28‑day window, per company disclosure at AD/PD 2026. The dataset supports further development in PD and related lysosomal‑dysfunction neurodegenerations. If replicated in larger trials, the result would be a notable proof‑of‑principle for oral PROTACs achieving central nervous system target engagement, a key regulatory and scientific milestone for targeted protein degradation in neurology.